MicroRNAs (miRNAs) are small non-coding single strand RNAs, 18-22 nucleotides long, that function as crucial post-transcriptional regulators of intracellular metabolic processes via mRNA degradation or inhibition.

miRNA biomarkers for the (early) diagnosis of various diseases including cancer, are in the spotlight as Next-Gen Molecular Diagnostic Tools that address the unmet needs of molecular diagnostics. Numerous research projects are currently underway to commercialize these biomarkers.

Accurate detection and analysis of miRNA using conventional Real-Time quantitative PCR (RT-qPCR) techniques is challenging due to short sequence length and high sequence similarity between miRNAs.


Liquid Biopsy


Early Cancer Screening

The primary objective of early cancer screening is to assess asymptomatic individuals for the presence of cancer cells to screen for early cancer(stage 1~2) in order to increase the cancer survival rate.

For early cancer screening of asymptomatic individuals to be feasible, diagnostic tests have to be minimally invasive and inexpensive so that repeated testing is possible. Thus, blood or urine based liquid biopsies are the best option that meets all the aforementioned criteria.



Using miRNA Biomarker

    Cell-free DNA (cfDNA) exist at low concentrations in the early stages of disease progression. Thus, early detection of diseases, including cancer, via liquid biopsy (blood, urine, etc.) of cfDNA is challenging.

Alternatively, circulating miRNAs exist at high concentrations in liquid specimens despite being in the early stages of disease progression, thus enabling effective early detection.

Patient-Oriented Diagnostics with Liquid Biopsy

Liquid biopsy offers a non-invasive and cost-effective alternative to tissue biopsies.

An Effective Tool for Early Cancer Diagnosis

Differential expression of miRNAs in cancer and other diseases facilitates its use as biomarkers.
miRNA-based diagnostics enable early detection and treatment thus improving patient outcomes and survival rates.

방문하신 것을 환영합니다.
현재 홈페이지 리뉴얼 작업 중입니다.
일부 페이지의 열람이 어려운 점 양해 바랍니다.
Do not see again